Fukuoka, Japan: Administration of the non-psychoactive cannabinoid cannabidiol (CBD) is neuroprotective against cerebral infarction (localized cell death in the brain) in mice, according to clinical trial data published in the May issue of the journal Stroke.
“Treatment of cannabidiol … significantly reduced the infarct volume … in mice” in a dose dependent manner, a research team at Fukuoka University’s Department of Neuropharmacology concluded. Authors speculated that CBD “exerts a neuroprotective effect through its anti-oxidant, anti-spasmodic, and anti-emetic activity, [as well as through] vasorelaxation.”
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the study, “Cannabidiol prevents cerebral infarction,” is available in the May issue of the journal Stroke.